It might be the latest version of a long-term strategic policy approach, but stakeholders need to ask themselves a critical question. Are they willing to trade a bridging fund and process changes for a few health technologies, based on the promise it could accelerate access, in return for a disinvestment framework and deprioritising most new therapies?
Stakeholders deserve clarity on the strategic objective before this process gets underway
November 25, 2024 Latest NewsBioPharmaComment
Latest Video
New Stories
-
If the minister is too embarrassed to respond, it might be the best of bad responses
September 19, 2025 - - Latest News -
Mark Butler acknowledges his concerns over potential impact of US pharmaceutical pricing reforms
September 19, 2025 - - Latest News -
CSL appoints new global head of search to accelerate innovation through strategic partnerships
September 18, 2025 - - Latest News -
Pharmacy Guild of Australia acquires Member Benefits Australia
September 18, 2025 - - Latest News -
Sanofi promotes a national dialogue on health literacy and trust
September 18, 2025 - - Latest News -
Island Pharmaceuticals reports breakthrough survival data for galidesivir in Marburg and Ebola studies
September 17, 2025 - - Australian Biotech -
Australian Dementia Network Registry wants access to 'turning point' therapies
September 17, 2025 - - Latest News